Page last updated: 2024-12-05
uvitex swn
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
Uvitex SWN: optical brightner from Ciba; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 7050 |
| CHEMBL ID | 315348 |
| CHEBI ID | 51938 |
| SCHEMBL ID | 67108 |
| MeSH ID | M0040258 |
Synonyms (103)
| Synonym |
|---|
| HMS1473C21 |
| BIDD:GT0821 |
| AC-16889 |
| CHEMBL315348 , |
| MLS002152891 |
| smr001224503 |
| bdbm50078833 |
| 7'-(diethylamino)-4-methylcoumarin |
| 91-44-1 |
| coumarin, 7-(diethylamino)-4-methyl- |
| wln: t66 bovj e1 in2&2 |
| coumarin 1 |
| 4-methyl-7-(diethylamino)coumarin |
| nsc61830 |
| 7-(diethylamino)-4-methylcoumarin |
| nsc-61830 |
| 2h-1-benzopyran-2-one, 7-(diethylamino)-4-methyl- |
| 7-(diethylamino)-4-methyl-2h-chromen-2-one |
| 7-(diethylamino)-4-methyl-chromen-2-one |
| IDI1_019383 |
| CHEMDIV3_000065 |
| NCGC00091624-01 |
| 7-diethylamino-4-methylcoumarin |
| calcofluor white sd |
| hakkol p |
| mdac |
| nsc 61830 |
| blancophor ffg |
| diethylaminomethylcoumarin |
| 7-(diethylamino)-4-methyl-2-benzopyrone |
| uvitex wgs |
| blancophor aw |
| hsdb 4244 |
| aclarat 8678 |
| 7d4mc |
| ai3-18869 |
| einecs 202-068-9 |
| 7-(diethylamino)-4-methyl-2h-1-benzopyran-2-one |
| coumarin, 7-diethylamino-4-methyl- |
| hiltamine artic white sol |
| ccris 5907 |
| c 47 |
| coumarin 460 |
| brn 0193303 |
| calcofluor white rw |
| 4-methyl-7-diethylaminocoumarin |
| coumarin 47 |
| inchi=1/c14h17no2/c1-4-15(5-2)11-6-7-12-10(3)8-14(16)17-13(12)9-11/h6-9h,4-5h2,1-3h |
| OPREA1_704968 |
| NCGC00172593-01 |
| CHEBI:51938 , |
| 7-diethylamino-4-methylcoumarin, 99% |
| AKOS001483296 |
| BRD-K26694113-001-01-7 |
| 7-(diethylamino)-4-methylchromen-2-one |
| STK874253 |
| M0631 |
| AF-960/00437064 |
| A843932 |
| NCGC00091624-03 |
| NCGC00091624-02 |
| HMS3039I13 |
| dtxsid9025035 , |
| dtxcid405035 |
| NCGC00257038-01 |
| cas-91-44-1 |
| tox21_303285 |
| NCGC00259338-01 |
| tox21_201789 |
| CCG-15101 |
| fluorescent brightener 140 |
| fluorescent brightener 52 |
| uvitex swn |
| unii-1sfj7f6r2c |
| c.i. 551100 |
| 1sfj7f6r2c , |
| FT-0619052 |
| 7-diethylamino-4-methylcoumarin [hsdb] |
| c.i. fluorescent brightener 140 |
| c.i. fluorescent brightener 52 |
| diethylaminomethylcoumarin [inci] |
| 7-diethylamino-4-methyl coumarin |
| SCHEMBL67108 |
| BBL027619 |
| 12224-03-2 |
| 7-(diethylamino)-4-methyl-2h-chromen-2-one # |
| 6zw , |
| SR-01000389311-1 |
| sr-01000389311 |
| mfcd00006864 |
| SY012944 |
| 2434_7-diethylamino-4-methylcoumarin |
| coumarin-1 |
| Q27123009 |
| 7-diethylamino-4-methylcoumarin (purified by sublimation) |
| AS-14613 |
| BCP27312 |
| AC2163 |
| mdac) |
| EN300-18465514 |
| CS-0009995 |
| HY-D0082 |
| D5730 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| fluorochrome | A fluorescent dye used to stain biological specimens. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| 7-aminocoumarins | Any member of the class of coumarins that contains a 7-amino-2H-chromen-2-one skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (80)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 34.2232 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342 |
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 43.4087 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 23.8819 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 36.4657 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 36.4657 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 37.7123 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 18.8523 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 56.2341 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 22.3872 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 44.6684 | 0.0013 | 7.7625 | 44.6684 | AID2120 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 46.6722 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 30.7271 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 31.6503 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795; AID1347036 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 40.0670 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533; AID720691; AID720692; AID720719 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 13.7436 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 29.5663 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 53.9771 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 29.7039 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220; AID743239 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 39.2031 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.6072 | 0.0002 | 29.3054 | 16,493.5996 | AID588514; AID743069; AID743075; AID743077; AID743078 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 39.8107 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 28.5431 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 35.2883 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 26.3972 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID588543; AID743222; AID743223; AID743241 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 44.6684 | 4.4668 | 18.3916 | 35.4813 | AID2107 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 33.1294 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 18.0652 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 64.0393 | 0.0016 | 28.0151 | 77.1139 | AID1259395 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 41.2142 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 39.9424 | 19.7391 | 45.9784 | 64.9432 | AID1159509; AID1159518 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 47.9903 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 23.7530 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 38.3512 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 24.2317 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 50.1187 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| snurportin-1 | Homo sapiens (human) | Potency | 50.1187 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 31.8343 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 50.1187 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 79.4328 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 28.1838 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 21.1446 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 12.5893 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 15.8489 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 35.5190 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 16.7855 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Caspase-7 | Homo sapiens (human) | Potency | 12.5893 | 3.9811 | 18.5856 | 31.6228 | AID889 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinal dehydrogenase 2 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 4.5000 | 4.5000 | 4.5000 | AID1441743 |
| Retinal dehydrogenase 1 | Homo sapiens (human) | IC50 (µMol) | 0.7600 | 0.0200 | 1.0476 | 6.7900 | AID1441741; AID1894012 |
| Retinal dehydrogenase 1 | Homo sapiens (human) | Ki | 1.0350 | 0.2850 | 0.7850 | 1.2000 | AID1441759; AID1441764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Immunoglobulin lambda variable 6-57 | Homo sapiens (human) | EC50 (µMol) | 5.6667 | 3.2400 | 5.6667 | 6.8800 | AID1776563; AID1776564 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | Kd | 130.0000 | 0.0001 | 0.5993 | 9.2000 | AID69097 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (276)
Molecular Functions (68)
Ceullar Components (39)
Bioassays (40)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1441739 | Inhibition of full length recombinant human ALDH1B1 expressed in Escherichia coli TunerDE3 assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence | |||
| AID1441759 | Non-competitive inhibition of full length recombinant human ALDH1A1 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level using varying levels propionaldehyde in presence of NAD+ by Lineweaver-B | |||
| AID1441749 | Inhibition of full length recombinant human ALDH2 expressed in Escherichia coli assessed as remaining dehydrogenase activity by measuring NAD(P)H level at 10 uM preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence of NA | |||
| AID1776563 | Stabilization of AL patient derived fluorescein-labeled IGLV6-57 T46L/F49Y mutant measured after 24 hrs by proteolysis coupled-fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. |
| AID1720849 | Kinetic stabilization of AL patient derived full length IGLV6-57 assessed as interconversion between bound and unbound light chains by NMR based CEST analysis | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. |
| AID1878281 | Stabilization of fluorescein-labelled amyloidogenic full length immunoglobulin light chain dimer (unknown origin) assessed as concentration of stabilizer that affords 50% maximal proteinase K protection by protease coupled fluorescence polarization assay | 2022 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 60 | Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. |
| AID1894012 | Inhibition of human ALDH1A1 | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors. |
| AID1441747 | Inhibition of full length recombinant human ALDH3A1 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of benzaldehyde as substrate in presence of | |||
| AID1439491 | Antihelmintic activity against Ascaridia galli | 2017 | European journal of medicinal chemistry, Mar-31, Volume: 129 | Medicinal plants used as anthelmintics: Ethnomedical, pharmacological, and phytochemical studies. |
| AID1441741 | Inhibition of full length recombinant human ALDH1A1 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence | |||
| AID1441753 | Lipophilicity, log P of the compound | |||
| AID1441764 | Non-competitive inhibition of full length recombinant human ALDH1A1 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level using varying levels acetaldehyde in presence of NAD+ by Lineweaver-Burk | |||
| AID1720848 | Kinetic stabilization of AL patient derived full length IGLV6-57 assessed as conformational exchange between bound and unbound light chains by measuring signal at 100 uM by [15N-1H]HSQC NMR spectra analysis | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. |
| AID1441750 | Inhibition of full length recombinant human ALDH3A1 expressed in Escherichia coli BL21(DE3) assessed as remaining dehydrogenase activity by measuring NAD(P)H level at 10 uM preincubated for 2 mins followed by addition of propionaldehyde as substrate in pr | |||
| AID1441743 | Inhibition of full length recombinant human ALDH1A2 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence | |||
| AID1878282 | Stabilization of fluorescein-labelled amyloidogenic full length immunoglobulin light chain dimer T46L/F49Y mutant (unknown origin) assessed as concentration of stabilizer that affords 50% maximal proteinase K protection by protease coupled fluorescence po | 2022 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 60 | Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. |
| AID1776565 | Stabilization of AL patient derived full length IgG L chain expressed in Escherichia coli BL21 (DE3) in pH 7.4 PBS buffer assessed as fold protection against proteinase K-mediated digestion by measuring fraction of unproteolyzed LC dimer at 10 uM incubate | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. |
| AID1878283 | Stabilization of fluorescein-labelled amyloidogenic full length immunoglobulin light chain dimer (unknown origin) assessed as fold proteinase K protection at 10 uM by protease coupled fluorescence polarization assay | 2022 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 60 | Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. |
| AID1720850 | Kinetic stabilization of AL patient derived recombinant full length IGLV6-57 C214S mutant assessed as induction of dimer formation at 100 uM by sedimentation velocity analytical ultracentrifugation | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. |
| AID1441745 | Inhibition of full length recombinant human ALDH1A3 expressed in Escherichia coli BL21(DE3) assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence | |||
| AID1439490 | Antihelmintic activity against Pheretima posthuma | 2017 | European journal of medicinal chemistry, Mar-31, Volume: 129 | Medicinal plants used as anthelmintics: Ethnomedical, pharmacological, and phytochemical studies. |
| AID1776564 | Stabilization of AL patient derived full length fluorescein-labeled IGLV6-57 expressed in Escherichia coli BL21 (DE3) measured after 24 hrs by proteolysis coupled-fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. |
| AID1441738 | Inhibition of full length recombinant human ALDH2 expressed in Escherichia coli assessed as reduction in dehydrogenase activity by measuring NAD(P)H level preincubated for 2 mins followed by addition of propionaldehyde as substrate in presence of NAD+ by | |||
| AID1441748 | Inhibition of full length recombinant human ALDH1A1 expressed in Escherichia coli BL21(DE3) assessed as remaining dehydrogenase activity by measuring NAD(P)H level at 10 uM preincubated for 2 mins followed by addition of propionaldehyde as substrate in pr | |||
| AID69097 | Dissociation constant when binding to FK506 binding protein (FKBP). | 1999 | Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14 | Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (28)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||